First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset

Mostrar otras versiones (1)

This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a programmed death ligand 1 (PD‐L1) tumor proportion score of 50% or higher e...

Descripción completa

Detalles Bibliográficos
Autores principales: Satouchi, Miyako, Nosaki, Kaname, Takahashi, Toshiaki, Nakagawa, Kazuhiko, Aoe, Keisuke, Kurata, Takayasu, Sekine, Akimasa, Horiike, Atsushi, Fukuhara, Tatsuro, Sugawara, Shunichi, Umemura, Shigeki, Saka, Hideo, Okamoto, Isamu, Yamamoto, Nobuyuki, Sakai, Hiroshi, Kishi, Kazuma, Katakami, Nobuyuki, Horinouchi, Hidehito, Hida, Toyoaki, Okamoto, Hiroaki, Atagi, Shinji, Ohira, Tatsuo, Han, Shi Rong, Noguchi, Kazuo, Ebiana, Victoria, Hotta, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734005/
https://www.ncbi.nlm.nih.gov/pubmed/32926507
http://dx.doi.org/10.1111/cas.14647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734005/
https://www.ncbi.nlm.nih.gov/pubmed/32926507
http://dx.doi.org/10.1111/cas.14647

Ejemplares similares